Rybelsus® 3 mg is an oral prescription medication used to improve blood sugar control in adults with type 2 diabetes, as an adjunct to diet and exercise. It contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, and is the first and only GLP-1 treatment available in tablet form.
Key Features:
-
Active Ingredient: Semaglutide 3 mg
-
Form: Oral tablet
-
Class: GLP-1 receptor agonist
-
Indication: For the treatment of type 2 diabetes mellitus in adults
How It Works:
Semaglutide mimics the function of the natural hormone GLP-1, enhancing insulin secretion, reducing glucagon levels, and slowing gastric emptying. This helps regulate blood glucose levels throughout the day.
Dosage & Administration:
Rybelsus 3 mg is typically prescribed as a starting dose to reduce gastrointestinal side effects. It is not intended for long-term maintenance. After 30 days, the dose is usually increased to 7 mg or 14 mg, depending on individual response and clinical goals. The tablet should be taken once daily, on an empty stomach, with no more than 4 ounces of water, and at least 30 minutes before any food, beverage, or other oral medications.
Benefits:
-
Convenient once-daily oral tablet—no injection required
-
Helps lower HbA1c and supports weight management in many patients
-
Can be combined with other diabetes medications as needed
Important Safety Information:
-
Not for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis
-
Contraindicated in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
-
May cause gastrointestinal side effects such as nausea, vomiting, or diarrhea
-
Risk of hypoglycemia increases when used with insulin or insulin secretagogues
Storage:
Store at room temperature between 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).
Note: Always use Rybelsus exactly as prescribed by your healthcare provider.
